Melanoma spheroids grown under neural crest cell conditions are highly plastic migratory/invasive tumor cells endowed with immunomodulator function

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Ramgolam, Kiran ^a   Lauriol, Jessica ^b   Lalou, Claude ^a   Lauden, Laura ^a   Michel, Laurence ^a   de la Grange, Pierre ^c   Khatib, Abdel Majid ^a   Aoudjit, Fawzi ^d   Charron, Dominique ^a,e   Alcaide Loridan, Catherine ^b   Al Daccak, Reem ^a  

^a INSERM   (France)

^b CNRS   (France)

^c UNIVERSITÉ PARIS DIDEROT   (France)

^d Université Laval   (Canada)

^e SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

KRUPPEL LIKE FACTOR 4; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR;

ARTICLE; CANCER STEM CELL; CARCINOGENICITY; CELL DIFFERENTIATION; CELL EXPANSION; CELL FUNCTION; CELL INVASION; CELL MIGRATION; CELL RENEWAL; CELL SUBPOPULATION; CONTROLLED STUDY; CULTURE MEDIUM; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MELANOMA; MELANOMA CELL; MESENCHYME CELL; NEURAL CREST CELL; PHENOTYPE; PLASTICITY; PREDICTION; SPHEROID CELL; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR SPHEROID; CANCER INVASION; CELL LINEAGE; CELL MOTION; CELL PROLIFERATION; DRUG EFFECT; EMBRYONIC STEM CELL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; IMMUNOLOGY; METABOLISM; MULTICELLULAR SPHEROID; NEURAL CREST; PATHOLOGY; PLURIPOTENT STEM CELL; TUMOR CELL CULTURE; TUMOR GENE;

CELL DIFFERENTIATION; CELL LINEAGE; CELL MOVEMENT; CELL PROLIFERATION; CULTURE MEDIA; EMBRYONIC STEM CELLS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; IMMUNOMODULATION; MELANOMA; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; NEURAL CREST; PHENOTYPE; PLURIPOTENT STEM CELLS; SPHEROIDS, CELLULAR; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 79954998528     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018784     Document Type: Article

References (72)

1. Fidler IJ, Kripke ML, (1977) Metastasis results from preexisting variant cells within a malignant tumor. Science 197: 893-895.
2. Levene A, (1980) On the histological diagnosis and prognosis of malignant melanoma. J Clin Pathol 33: 101-124.
3. Banerjee SS, Harris M, (2000) Morphological and immunophenotypic variations in malignant melanoma. Histopathology 36: 387-402.
4. Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, et al. (2005) The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A 102: 6092-6097.
5. Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, et al. (2006) Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 19: 290-302.
6. Jeffs AR, Glover AC, Slobbe LJ, Wang L, He S, et al. (2009) A gene expression signature of invasive potential in metastatic melanoma cells. PLoS One 4: e8461.
7. Hoek KS, Eichhoff OM, Schlegel NC, Dobbeling U, Kobert N, et al. (2008) In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res 68: 650-656.
8. Hendrix MJ, Seftor EA, Hess AR, Seftor RE, (2003) Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 3: 411-421.
9. Kulesa PM, Kasemeier-Kulesa JC, Teddy JM, Margaryan NV, Seftor EA, et al. (2006) Reprogramming metastatic melanoma cells to assume a neural crest cell-like phenotype in an embryonic microenvironment. Proc Natl Acad Sci U S A 103: 3752-3757.
10. Lee LM, Seftor EA, Bonde G, Cornell RA, Hendrix MJ, (2005) The fate of human malignant melanoma cells transplanted into zebrafish embryos: assessment of migration and cell division in the absence of tumor formation. Dev Dyn 233: 1560-1570.
11. Postovit LM, Margaryan NV, Seftor EA, Kirschmann DA, Lipavsky A, et al. (2008) Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells. Proc Natl Acad Sci U S A 105: 4329-4334.
12. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, et al. (2005) A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65: 9328-9337.
13. Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, et al. (2007) Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 43: 935-946.
14. Perego M, Tortoreto M, Tragni G, Mariani L, Deho P, et al. (2010) Heterogeneous phenotype of human melanoma cells with in vitro and in vivo features of tumor-initiating cells. J Invest Dermatol 130: 1877-1886.
15. Schatton T, Frank MH, (2010) The in vitro spheroid melanoma cell culture assay: cues on tumor initiation? J Invest Dermatol 130: 1769-1771.
16. Raz A, Ben-Ze'ev A, (1983) Modulation of the metastatic capability in B16 melanoma by cell shape. Science 221: 1307-1310.
17. Stackpole CW, Fornabaio DM, Alterman AL, (1985) Phenotypic interconversion of B16 melanoma clonal cell populations: relationship between metastasis and tumor growth rate. Int J Cancer 35: 667-674.
18. Coucke PH, De Pauw-Gillet MC, Bonjean KA, Siwek BL, Foidart JM, et al. (1994) Characterization and tumorigenicity of spheroids composed of pigmented or non pigmented B16 melanoma cells. In Vivo 8: 333-338.
19. Ghosh S, Spagnoli GC, Martin I, Ploegert S, Demougin P, et al. (2005) Three-dimensional culture of melanoma cells profoundly affects gene expression profile: a high density oligonucleotide array study. J Cell Physiol 204: 522-531.
20. Wong CE, Paratore C, Dours-Zimmermann MT, Rochat A, Pietri T, et al. (2006) Neural crest-derived cells with stem cell features can be traced back to multiple lineages in the adult skin. J Cell Biol 175: 1005-1015.
21. Jiang X, Gwye Y, McKeown SJ, Bronner-Fraser M, Lutzko C, et al. (2008) Isolation and Characterization of Neural Crest Stem Cells Derived from In Vitro-Differentiated Human Embryonic Stem Cells. Stem Cells Dev.
22. Martins I, Deshayes F, Baton F, Forget A, Ciechomska I, et al. (2007) Pathologic expression of MHC class II is driven by mitogen-activated protein kinases. Eur J Immunol 37: 788-797.
23. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
24. de la Grange P, Dutertre M, Correa M, Auboeuf D, (2007) A new advance in alternative splicing databases: from catalogue to detailed analysis of regulation of expression and function of human alternative splicing variants. BMC Bioinformatics 8: 180.
25. Clark TA, Schweitzer AC, Chen TX, Staples MK, Lu G, et al. (2007) Discovery of tissue-specific exons using comprehensive human exon microarrays. Genome Biol 8: R64.
26. Gardina PJ, Clark TA, Shimada B, Staples MK, Yang Q, et al. (2006) Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array. BMC Genomics 7: 325.
27. French PJ, Peeters J, Horsman S, Duijm E, Siccama I, et al. (2007) Identification of differentially regulated splice variants and novel exons in glial brain tumors using exon expression arrays. Cancer Res 67: 5635-5642.
28. Thorsen K, Sorensen KD, Brems-Eskildsen AS, Modin C, Gaustadnes M, et al. (2008) Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Mol Cell Proteomics 7: 1214-1224.
29. Xi L, Feber A, Gupta V, Wu M, Bergemann AD, et al. (2008) Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer. Nucleic Acids Res 36: 6535-6547.
30. Thomas PD, Kejariwal A, Guo N, Mi H, Campbell MJ, et al. (2006) Applications for protein sequence-function evolution data: mRNA/protein expression analysis and coding SNP scoring tools. Nucleic Acids Res 34: W645-650.
31. Hofmann UB, Westphal JR, Van Kraats AA, Ruiter DJ, Van Muijen GN, (2000) Expression of integrin alpha(v)beta(3) correlates with activation of membrane-type matrix metalloproteinase-1 (MT1-MMP) and matrix metalloproteinase-2 (MMP-2) in human melanoma cells in vitro and in vivo. Int J Cancer 87: 12-19.
32. Mills L, Tellez C, Huang S, Baker C, McCarty M, et al. (2002) Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res 62: 5106-5114.
33. Flammiger A, Besch R, Cook AL, Maier T, Sturm RA, et al. (2009) SOX9 and SOX10 but not BRN2 are required for nestin expression in human melanoma cells. J Invest Dermatol 129: 945-953.
34. Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ, et al. (2007) Increased expression of stem cell markers in malignant melanoma. Mod Pathol 20: 102-107.
35. Lunter PC, van Kilsdonk JW, van Beek H, Cornelissen IM, Bergers M, et al. (2005) Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity. Cancer Res 65: 8801-8808.
36. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872.
37. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, et al. (2008) Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451: 141-146.
38. Schoenhals M, Kassambara A, De Vos J, Hose D, Moreaux J, et al. (2009) Embryonic stem cell markers expression in cancers. Biochem Biophys Res Commun 383: 157-162.
39. Suva ML, Riggi N, Stehle JC, Baumer K, Tercier S, et al. (2009) Identification of cancer stem cells in Ewing's sarcoma. Cancer Res 69: 1776-1781.
40. Schatton T, Frank MH, (2008) Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res 21: 39-55.
41. Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, et al. (2005) ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 65: 4320-4333.
42. Huls M, Russel FG, Masereeuw R, (2009) The role of ATP binding cassette transporters in tissue defense and organ regeneration. J Pharmacol Exp Ther 328: 3-9.
43. Balemans W, Van Hul W, (2002) Extracellular regulation of BMP signaling in vertebrates: a cocktail of modulators. Dev Biol 250: 231-250.
44. Vigouroux S, Yvon E, Wagner HJ, Biagi E, Dotti G, et al. (2003) Induction of antigen-specific regulatory T cells following overexpression of a Notch ligand by human B lymphocytes. J Virol 77: 10872-10880.
45. Rutz S, Mordmuller B, Sakano S, Scheffold A, (2005) Notch ligands Delta-like1, Delta-like4 and Jagged1 differentially regulate activation of peripheral T helper cells. Eur J Immunol 35: 2443-2451.
46. Palacios R, Goni J, Martinez-Forero I, Iranzo J, Sepulcre J, et al. (2007) A network analysis of the human T-cell activation gene network identifies JAGGED1 as a therapeutic target for autoimmune diseases. PLoS One 2: e1222.
47. McFadden C, Morgan R, Rahangdale S, Green D, Yamasaki H, et al. (2007) Preferential migration of T regulatory cells induced by IL-16. J Immunol 179: 6439-6445.
48. Kuriyama S, Mayor R, (2008) Molecular analysis of neural crest migration. Philos Trans R Soc Lond B Biol Sci 363: 1349-1362.
49. Gupta PB, Kuperwasser C, Brunet JP, Ramaswamy S, Kuo WL, et al. (2005) The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet 37: 1047-1054.
50. Neufeld G, Kessler O, (2008) The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nat Rev Cancer 8: 632-645.
51. Capparuccia L, Tamagnone L, (2009) Semaphorin signaling in cancer cells and in cells of the tumor microenvironment-two sides of a coin. J Cell Sci 122: 1723-1736.
52. Suzuki K, Kumanogoh A, Kikutani H, (2008) Semaphorins and their receptors in immune cell interactions. Nat Immunol 9: 17-23.
53. Klyushnenkova E, Mosca JD, Zernetkina V, Majumdar MK, Beggs KJ, et al. (2005) T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 12: 47-57.
54. Refaeli Y, Bhoumik A, Roop DR, Ronai ZA, (2009) Melanoma-initiating cells: a compass needed. EMBO Rep.
55. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, et al. (2008) Efficient tumour formation by single human melanoma cells. Nature 456: 593-598.
56. Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, et al. (2010) Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18: 510-523.
57. Wu C, Alman BA, (2008) Side population cells in human cancers. Cancer Lett 268: 1-9.
58. Rappa G, Mercapide J, Anzanello F, Prasmickaite L, Xi Y, et al. (2008) Growth of cancer cell lines under stem cell-like conditions has the potential to unveil therapeutic targets. Exp Cell Res 314: 2110-2122.
59. Fukunaga-Kalabis M, Martinez G, Nguyen TK, Kim D, Santiago-Walker A, et al. Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population. Oncogene 29: 6115-6124.
60. Hendrix MJ, Seftor EA, Seftor RE, Kasemeier-Kulesa J, Kulesa PM, et al. (2007) Reprogramming metastatic tumour cells with embryonic microenvironments. Nat Rev Cancer 7: 246-255.
61. Widera D, Zander C, Heidbreder M, Kasperek Y, Noll T, et al. (2009) Adult Palatum as a Novel Source of Neural-Crest Related Stem Cells. Stem Cells.
62. Strizzi L, Abbott DE, Salomon DS, Hendrix MJ, (2008) Potential for cripto-1 in defining stem cell-like characteristics in human malignant melanoma. Cell Cycle 7: 1931-1935.
63. Klarmann GJ, Hurt EM, Mathews LA, Zhang X, Duhagon MA, et al. (2009) Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis 26: 433-446.
64. Yu SC, Bian XW, (2009) Enrichment of cancer stem cells based on heterogeneity of invasiveness. Stem Cell Rev Rep 5: 66-71.
65. Martins I, Sylla K, Deshayes F, Lauriol J, Ghislin S, et al. (2009) Coexpression of major histocompatibility complex class II with chemokines and nuclear NFkappaB p50 in melanoma: a rational for their association with poor prognosis. Melanoma Res 19: 226-237.
66. Aoudjit F, Guo W, Gagnon-Houde JV, Castaigne JG, Alcaide-Loridan C, et al. (2004) HLA-DR signaling inhibits Fas-mediated apoptosis in A375 melanoma cells. Exp Cell Res 299: 79-90.
67. Ostmeier H, Fuchs B, Otto F, Mawick R, Lippold A, et al. (2001) Prognostic immunohistochemical markers of primary human melanomas. Br J Dermatol 145: 203-209.
68. Byrne SN, Halliday GM, (2003) High levels of Fas ligand and MHC class II in the absence of CD80 or CD86 expression and a decreased CD4+ T cell Infiltration, enables murine skin tumours to progress. Cancer Immunol Immunother 52: 396-402.
69. Wang HY, Peng G, Guo Z, Shevach EM, Wang RF, (2005) Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells. J Immunol 174: 2661-2670.
70. Schatton T, Schutte U, Frank NY, Zhan Q, Hoerning A, et al. (2010) Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res 70: 697-708.
71. Matsumoto Y, Fujita T, Hirai I, Sahara H, Torigoe T, et al. (2009) Immunosuppressive effect on T cell activation by interleukin-16- and interleukin-10-cDNA-double-transfected human squamous cell line. Burns 35: 383-389.
72. Wei J, Barr J, Kong LY, Wang Y, Wu A, et al. (2010) Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res 16: 461-473.